VCs in funding round for Cevec

Existing investors include Peppermint Venture Partners, NRW Bank, ERP Startfonds and Creathor Ventures.

Creathor is currently investing from its €80m Creathor Venture III vehicle, which typically takes 30% stakes in companies. Peppermint Venture is currently investing from its Charité Biomedical Fund, which closed on €31m in 2010.

The fresh capital will go towards scaling up the manufacturing operation for industrial use and the commercialisation of the company's platform. In addition, Cevec plans to further expand its portfolio of cell lines.

Previous funding
In 2009, NRW and Creathor led a €4m funding round for Cevec. ERP Startfonds – a venture capital fund of KFW's – also participated.

The three investors joined forces again for a $5.4m series-B funding round in 2010, and again for a €6m funding round in 2011.

Peppermint led a €2.8m funding round in 2012. NRW and Creathor also participated.

Peppermint, NRW and Creathor raised €4.5m for a funding round in 2015.

Company
Cevec produces biopharmaceutical drugs such as recombinant glycoproteins and gene therapy vectors. The company is based in Cologne, was founded in 2003 and employs 30 people.

People
Cevec – Nicole Faust (chief executive officer, chief scientific officer).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• DACH
• Healthcare
• healthcare
• Germany
• Venture